BioSpace News Archive

The studies employ unique therapeutic approaches and advanced engineering technologies such as the gene-editing platform CRISPR/Cas9, reflecting the fruits of many years of research dedication and innovation.

The pooled analysis also found that patients who were treated with ibrutinib earlier, after their first relapse/progression, experienced higher rates of OS and PFS.

Tetra Bio-Pharma announced today that the Company has accepted the suggestion of Health Canada to change the order of its clinical trial application (CTA) review process.

BioMarin announced today an update to its previously reported results of an open-label Phase I/II study of valoctocogene roxaparvovec.

The new RESONATE-2 data will be presented at the 59th ASH Annual Meeting and Exposition on Dec. 9 in Atlanta.

In 27 NSCLC patients who had received a median of two prior therapies, AM0010 in combination with either nivolumab or pembrolizumab induced a durable rate of tumor shrinkage of 41%.

Seattle Genetics, Inc. today highlighted updated results from the phase 3 ALCANZA clinical trial evaluating ADCETRIS (brentuximab vedotin) in CD30-expressing cutaneous T-cell lymphoma (CTCL) at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Atlanta, Georgia, December 9-12, 2017.

Magenta Therapeutics announced the presentation of preclinical data from its CD117 antibody-drug conjugate (ADC) conditioning program.

These data include longer-term results from the pivotal HAVEN 1 and HAVEN 2 studies in people with hemophilia A with inhibitors to factor VIII, showing once-weekly subcutaneous HEMLIBRA prophylaxis demonstrated superior efficacy compared to prior treatment with bypassing agents (BPAs) as prophylaxis or on-demand.

Data from the oral presentation at the 59th American Society of Hematology Annual Meeting (ASH) held in Atlanta, Georgia demonstrate that ALX148 triggers a broad antitumor response by bridging innate and adaptive immunity.